Pharmaceutical Therapy-related Quality of Life among University Students Treated with Antidepressants
Article Sidebar
Main Article Content
Abstract
Objective: To examine the pharmaceutical therapy-related quality of life in university students treated with antidepressants. Methods: This cross-sectional descriptive study collected data from 76 undergraduate and graduate students receiving treatment with antidepressants at Student Wellness of Chulalongkorn University between March to June 2023. Pharmaceutical therapy related quality of life was assessed using the short version of the Patient-Reported Outcomes Measure of Pharmaceutical Therapy (PROMPT). Results: Mean age of the subjects was 21.33±2.94 years. The scores on all eight domains (16 items) of the PROMPT were at the moderate to good level (within the range of 51-75 out of the full score of 100). Average scores on each domain were as follows: (a) medicine and disease information (59.08±18.61); (b) medicine effectiveness (59.87±20.65); (c) impacts of medicines and side-effects (55.59±26.33); (d) psychological impacts of medication use (60.20±23.16); (e) convenience mean (68.75±27.12); (f) availability and accessibility (70.39±29.92); (g) therapeutic relationship with healthcare providers (70.39±27.00); and (h) overall quality of life (59.54±22.35). Conclusion: The results of the research reveal the pharmaceutical therapy related-quality of life in each domain in university students receiving antidepressants which is useful for monitoring patients and further improving the pharmaceutical care service.
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
ผลการวิจัยและความคิดเห็นที่ปรากฏในบทความถือเป็นความคิดเห็นและอยู่ในความรับผิดชอบของผู้นิพนธ์ มิใช่ความเห็นหรือความรับผิดชอบของกองบรรณาธิการ หรือคณะเภสัชศาสตร์ มหาวิทยาลัยสงขลานครินทร์ ทั้งนี้ไม่รวมความผิดพลาดอันเกิดจากการพิมพ์ บทความที่ได้รับการเผยแพร่โดยวารสารเภสัชกรรมไทยถือเป็นสิทธิ์ของวารสารฯ
References
Shorey S, Ng ED, Wong CHJ. Global prevalence of depression and elevated depressive symptoms among adolescents: A systematic review and meta-analysis. Br J Clin Psychol. 2022; 61: 287-305.
Thapar A, Collishaw S, Pine DS, Thapar AK. Depression in adolescence. Lancet. 2012; 379: 1056-67.
Maughan B, Collishaw S, Stringaris A. Depression in childhood and adolescence. J Can Acad Child Adolesc Psychiatry 2013; 22: 35-40.
Weersing VR, Shamseddeen W, Garber J, Hollon SD, Clarke GN, Beardslee WR, et al. Prevention of depression in at-risk adolescents: predictors and moderators of acute effects. J Am Acad Child Adolesc Psychiatry 2016; 55: 219-26.
DeFilippis M, Wagner KD. Management of treatment-resistant depression in children and adolescents. Paediatr Drugs 2014; 16: 353-61.
Sabella D. Antidepressant medications. Am J Nurs 2018; 118: 52-9.
Cipriani A, Zhou X, Del Giovane C, Hetrick SE, Qin B, Whittington C, et al. Comparative efficacy and tolerability of antidepressants for major depressive disorder in children and adolescents: a network meta-analysis. Lancet. 2016; 388: 881-90.
Jane Garland E, Kutcher S, Virani A, Elbe D. Update on the use of SSRIs and SNRIs with children and adolescents in clinical practice. J Can Acad Child Adolesc Psychiatry 2016; 25: 4-10.
Hazell P, Mirzaie M. Tricyclic drugs for depression in children and adolescents. Cochrane Database Syst Rev. 2013; 2013: CD002317. doi: 10.1002/14651858 .CD002317.pub2.
Locher C, Koechlin H, Zion SR, Werner C, Pine DS, Kirsch I, et al. Efficacy and safety of selective serotonin reuptake inhibitors, serotonin-norepine- phrine reuptake inhibitors, and placebo for common psychiatric disorders among children and adolescents: A systematic review and meta-analysis. JAMA Psychiatry. 2017; 74: 1011-20.
Cochran W. Sampling techniques. 3 rd ed. New York: John Wiley & Sons; 1977.
Sakthong P, Chinthammit C, Sukarnjanaset P, Sonsa-Ardjit N, Munpan W. Psychometric properties of the Patient-Reported Outcomes Measure of Pharmaceutical Therapy for Quality of Life (PROMPT-QOL). Value Health Reg Issues. 2017; 12: 41-9.
Sakthong P, Suksanga P, Sakulbumrungsil R, Winit-Watjana W. Development of Patient-reported Outcomes Measure of Pharmaceutical Therapy for Quality of Life (PROMPT-QoL): A novel instrument for medication management. Res Social Adm Pharm. 2015; 11: 315-38.
Sakthong P, Sonsa-Ardjit N, Sukarnjanaset P, Munpan W, Sangthonganotai T. Development and psychometrics of a short-form pharmaceutical care-specific measure for quality of life. Int J Clin Pharm. 2018; 40: 642-9.
Mishra A, Krishna GS, Alla S, Kurian TD, Kurian J, Ramesh M, et al. Impact of pharmacist-psychiatrist collaborative patient education on medication adherence and quality of life (QOL) of bipolar affective disorder (BPAD) patients. Front Pharmacol. 2017; 8: 722.
Parihar A, Ganachari MS, Tekkalaki B, Shashikala W. The impact of clinical pharmacist lead collaborative care on quality of life of the patients with bipolar disorder: A unicenter prospective, randomiza- tion study. Indian Journal of Pharmaceutical Education and Research. 2017; 51: s129-35.
Sell R, Schaefer M. Prevalence and risk factors of drug-related problems identified in pharmacy-based medication reviews. Int J Clin Pharm 2020; 42: 588-97.
